ELU001 / Elucida Oncology 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  ELU001 / Elucida Oncology
    Enrollment closed, Enrollment change, Trial completion date:  ELU-FR?-1: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FR?) (clinicaltrials.gov) -  Jun 25, 2024   
    P1/2,  N=79, Active, not recruiting, 
    Trial completion date: Sep 2024 --> Jun 2024 | Active, not recruiting --> Terminated; Lack of Funding - no safety issue with Drug; Company Permanently Closed Recruiting --> Active, not recruiting | N=166 --> 79 | Trial completion date: Jun 2025 --> Sep 2024
  • ||||||||||  ELU001 / Elucida Oncology
    Clinical Translation & Initial Clinical Safety Results of ELU001, an Anti-Folate Receptor Alpha C () -  Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_126;    
    N=21 --> 0 | Not yet recruiting --> Withdrawn Reviewing the preclinical development of ELU001 and how it guided the design of the initial clinical trial will be presented; Exploring the selection of appropriate models for the nonclinical toxicology studies of ELU001 to guide initial safety trials; Reiterating how the nonclinical toxicology studies of ELU001 and historical studies with the free exatecan payload accurately identified its clinical safety profile
  • ||||||||||  ELU001 / Elucida Oncology
    Trial completion date, Trial primary completion date:  ELU-FR?-1: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FR?) (clinicaltrials.gov) -  Jul 28, 2023   
    P1/2,  N=166, Recruiting, 
    Reviewing the preclinical development of ELU001 and how it guided the design of the initial clinical trial will be presented; Exploring the selection of appropriate models for the nonclinical toxicology studies of ELU001 to guide initial safety trials; Reiterating how the nonclinical toxicology studies of ELU001 and historical studies with the free exatecan payload accurately identified its clinical safety profile Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Jun 2024
  • ||||||||||  ELU001 / Elucida Oncology
    Phase 1 trial of a novel C (On Demand | Hall A; Poster Bd # 354a) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_1858;    
    P1/2
    The study is enrolling in Part 1 Q2W Cohort 301 and Q3W Cohort A in the US. Clinical trial information: NCT05001282.
  • ||||||||||  ELU001 / Elucida Oncology
    Preclinical development of ELU001: A folate receptor alpha (FR?)-targeted C (Section 30; Poster Board #27) -  Mar 14, 2023 - Abstract #AACR2023AACR_2169;    
    Retreatment of these animals resulted in an additional decrease in tumor burden. These results suggest that ELU001 may have promise for the treatment of metastatic brain tumors that are difficult to treat with currently available agents.
  • ||||||||||  ELU001 / Elucida Oncology
    Outlining the Exciting Clinical Progress of ELU001 () -  Jan 2, 2023 - Abstract #ADCLondon2023ADC_London_137;    
    These results suggest that ELU001 may have promise for the treatment of metastatic brain tumors that are difficult to treat with currently available agents. • Learn about ELU001, a ligandconjugated nanoparticle targeting folate receptor alpha • Discussing the clinical Phase I/II results of ELU001 • Outlining the future opportunities for this novel format
  • ||||||||||  ELU001 / Elucida Oncology
    Journal:  Ultrasmall Folate Receptor Alpha Targeted Enzymatically Cleavable Silica Nanoparticle Drug Conjugates Augment Penetration and Therapeutic Efficacy in Models of Cancer. (Pubmed Central) -  Oct 21, 2022   
    When compared with an anti-FRα-DM4 ADC, EC112002 demonstrated deeper penetration into 3D cell-line-derived tumor spheroids and superior specific cytotoxicity in a panel of 3D patient-derived tumor spheroids, as well as enhanced efficacy in cell-line-derived and patient-derived in vivo tumor xenograft models expressing a range of low to high levels of FRα. With the growing interest in developing clinically translatable, safe, and efficacious DDSs, EC112002 has the potential to address some of the critical limitations of the current systemic drug delivery for cancer management.
  • ||||||||||  ELU001 / Elucida Oncology
    Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001. folate receptor alpha-directed C’Dot-drug-conjugate (Section 22) -  Mar 9, 2022 - Abstract #AACR2022AACR_3222;    
    P1/2
    ELU001 was well tolerated with an apparent maximum tolerance dose of 1.50 mg/kg/mouse (0.5 mg/kg exatecan, Q3DX3). In summary, we demonstrated that ELU001 is highly effective at eliminating FOLR1 positive AML cells in vitro and in vivo, providing the preclinical data to support further assessment of ELU001 in clinical trials for pediatric patients with CBFA2T3-GLIS2 fusions overexpressing FOLR1.
  • ||||||||||  ELU001 / Elucida Oncology
    Enrollment open:  ELU-FR?-1: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FR?) (clinicaltrials.gov) -  Sep 8, 2021   
    P1/2,  N=166, Recruiting, 
    In summary, we demonstrated that ELU001 is highly effective at eliminating FOLR1 positive AML cells in vitro and in vivo, providing the preclinical data to support further assessment of ELU001 in clinical trials for pediatric patients with CBFA2T3-GLIS2 fusions overexpressing FOLR1. Not yet recruiting --> Recruiting